MOBI Overview

Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.

Wall Street analysts forecast MOBI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOBI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mobia Medical Inc revenue for the last quarter amounts to 10.69M USD, increased 144.16

Mobia Medical Inc. EPS for the last quarter amounts to -0.42 USD, increased 100.00

Mobia Medical Inc (MOBI) has 167 emplpoyees as of June 27 2026.

Today MOBI has the market capitalization of 486.43M USD.